Last reviewed · How we verify
NCT05516199: EXPRESS-MOM
Antenatal Breastmilk Expression From Week 34 of Gestation
NA trial testing Antenatal breastmilk expression in Breastmilk Expression in 60 participants. Completed in 30 November 2023.
30 September 2023
Quick facts
| Lead sponsor | Odense University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 60 |
| Start date | 31 August 2022 |
| Primary completion | 30 September 2023 |
| Estimated completion | 30 November 2023 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Antenatal breastmilk expression
- Breastfeeding consultation
Conditions studied
- Breastmilk Expression — all drugs for Breastmilk Expression →
- Collection, Breastmilk — all drugs for Collection, Breastmilk →
- Breastfeeding — all drugs for Breastfeeding →
- Healthy — all drugs for Healthy →
Sponsor
Odense University Hospital
Who can join
Adults 18 to 45, female only, with Breastmilk Expression or Collection, Breastmilk. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this pilot study, the investigators aim to examine if antenatal breastmilk expression from week 34 of pregnancy is a safe and feasible procedure for the mother and fetus. Furthermore, the investigators want to evaluate breastfeeding rates.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Safety of antenatal breastmilk expression from week 34 of pregnancy: a randomized controlled pilot study (The Express-MOM study).
Simonsen MB, Bentzen SB, Möller S, Holm KG, et al · · 2025 · cited 2× · PMID 39748396 · DOI 10.1186/s40748-024-00197-1 -
Women's bodily experience of antenatal breastmilk expression from 34 weeks of gestation: Qualitative results from the Express-MOM study.
Bentzen SB, Simonsen MB, Zachariassen G, Vinter CA, et al · · 2024 · cited 1× · PMID 39493541 · DOI 10.18332/ejm/193601
Verify or expand the search:
- PubMed search for NCT05516199
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Odense University Hospital trials
Trials by the same sponsor.
- NCT07163091 — Bracing After Ankle Fracture · NA · not yet recruiting
- NCT07521696 — Physical Recovery During Bracing After Ankle Fracture (Re-BAF) · NA · not yet recruiting
- NCT07466212 — QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy · not yet recruiting
- NCT07191379 — Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma · Phase 4 · not yet recruiting
- NCT07170085 — Positioning of Children With Acute Respiratory Insufficiency · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05516199 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Odense University Hospital
- Last refreshed: 16 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05516199.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing